Synonyms: DS-1594a | DS-1594b
Compound class:
Synthetic organic
Comment: Emilumenib (DS-1594) is an orally available small-molecule menin inhibitor [1]. It binds to the nuclear protein menin (MEN1) and prevents its interaction with menin-mixed lineage leukemia (MLL; KMT2A, lysine methyltransferase 2A), as a mechanism to disrupt proleukemogenic signalling via the menin-KMT2A complex in acute leukemias with KMT2A rearrangements.
|
|
No information available. |
Summary of Clinical Use ![]() |
DS-1594 was advanced to clinical evaluation for efficacy in acute leukemias with KMT2A or nucleophosmin 1 (NPM1) rearrangements. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Phase 1/Phase 2 Interventional | M.D. Anderson Cancer Center |